PATENT CLAIM ANALYSIS

Application Number: 15865404
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["424", "489000"]

Abstract:
Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

Claim (Index 14):
The method of  claim 12 , wherein the non-normothermic state is heat stroke.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 86.0
- Lexical Diversity: 1.53535
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15144124', '13353478', '10788413', '12717588', '13353480']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.778735983246317
- 35 USC 102 Novelty (BERT): 0.548166371372293
- Combined Prediction Score: 0.7556790220589146
- Mean Citation Score: 400.61187200000006
- Max Citation Score: 415.7883
- Similarity Product: 239.47397633003

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test